Catheter Precision, Inc. (VTAK) Stock Analysis and Metrics

Catheter Precision

NYSE: VTAK

$0.26 ▼ -0.15 (-36.67%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap0.80

P/E-0.07

P/S0.00

Div. Yield0.00

Total Debt (Qtr)6.54 Mn

Revenue Growth (1y) (Qtr)202.10

Add ratio to table…

About

Catheter Precision Inc is a medical technology company focused on the design, manufacture, and sale of innovative products for cardiac electrophysiology procedures. The company’s primary offerings include the VIVO System, a non-invasive imaging tool for 3D cardiac mapping to localize ventricular arrhythmia origins, and LockeT, a suture retention device for wound healing and efficient suture management. Catheter Precision Inc operates within the healthcare sector, specifically serving the electrophysiology market which addresses diagnosis and treatment of heart rhythm disorders.

Catheter Precision Inc generates revenue through the sale of its VIVO System and LockeT products to hospitals and electrophysiology labs. The VIVO System requires disposable VIVO Positioning Patches for each procedure, creating a recurring revenue stream. LockeT is sold as a sterile, single-use device. The company also sells the Amigo Remote Catheter System, a robotic arm for catheter control, though this product is currently under evaluation for future development and not a primary revenue driver. Sales occur both domestically through direct sales teams and internationally via distributors.

The company operates through the following segments:

• VIVO System segment includes the non-invasive 3D cardiac mapping system, associated software, disposable Positioning Patches, and related clinical support activities used to localize ventricular arrhythmia origins prior to ablation procedures.

• LockeT segment includes the suture retention device indicated for wound healing by distributing suture tension, securing sutures, and aiding in their efficient location and removal during vascular access procedures.

• Amigo segment includes the Remote Catheter System, a robotic arm device for catheter control, which is owned by the company and under consideration for future research and development of a second-generation product.

Catheter Precision Inc holds a niche position in the competitive electrophysiology market dominated by large medical device companies such as Medtronic Plc Abbott Laboratories Biosense Webster (a division of Johnson & Johnson) and Boston Scientific Corp. The company differentiates itself through its non-invasive VIVO System which reduces procedure time and anesthesia exposure by enabling pre-procedural localization of arrhythmia sites. LockeT offers advantages over traditional vascular closure devices by improving hemostasis reducing time to ambulation and lowering procedural costs. The company’s focus on underserved ventricular arrhythmia treatment and its portfolio of FDA-cleared and CE-marked products support its competitive standing.

Catheter Precision Inc serves hospitals and electrophysiology labs performing cardiac ablation procedures. The company’s primary customers are healthcare institutions providing ventricular and atrial fibrillation treatments. During fiscal 2025 two individual customers represented approximately 28% and 12% of total revenues respectively with three customers collectively accounting for about 50% of revenue. The company estimates there are 2,000 to 3,000 electrophysiology labs in the U. S. and a similar number internationally performing approximately 600,000 ablation procedures annually.

Investment Thesis

▲ Bull case

VTAK's strategic investment in Volato Group represents a significant pivot toward high-growth AI infrastructure opportunities that the market is currently underestimating, particularly given the company's existing ownership of Parslee, an AI software platform with proven capabilities in enhancing large language model reliability through deterministic document intelligence. This foundational asset provides VTAK with immediate operational expertise and intellectual property in a niche but critical segment of the AI value chain—auditability and compliance—which is becoming increasingly vital as enterprises scale AI adoption under tightening regulatory scrutiny. The investment not only strengthens Volato's balance sheet with $2.2 million in restricted common stock but also signals VTAK's commitment to leveraging its public company platform to access and scale AI-driven opportunities, a move that could unlock substantial upside if management fees, carried interest, or equity appreciation from future acquisitions in AI data centers, power generation, or compute infrastructure—sectors experiencing explosive demand due to the AI boom. Management's explicit focus on evaluating AI infrastructure, software, data infrastructure, compute, and power generation assets reflects a structural shift toward capital-intensive, high-barrier-to-entry opportunities that align with long-term secular trends, positioning VTAK to benefit from multiple expansion as investors re-rate the company from a legacy medical device player to an AI infrastructure holding company with tangible operating assets and deal flow. The fact that VTAK led this investment as the largest shareholder, coupled with CEO David Jenkins' public endorsement of Volato's unique combination of technology assets and public market access, underscores confidence in the strategy's viability and suggests that further capital allocation toward similar AI opportunities is likely, potentially creating a virtuous cycle of deal sourcing, execution, and value creation that the market has not yet priced in.

VTAK's strategic investment in Volato Group represents a significant pivot toward high-growth AI infrastructure opportunities that the market is currently underestimating, particularly given the company's existing ownership of Parslee, an AI software platform with proven capabilities in enhancing large language model reliability through deterministic document intelligence. This foundational asset provides VTAK with immediate operational expertise and intellectual property in a niche but critical segment of the AI value chain—auditability and compliance—which is becoming increasingly vital as enterprises scale AI adoption under tightening regulatory scrutiny. The investment not only strengthens Volato's balance sheet with $2.2 million in restricted common stock but also signals VTAK's commitment to leveraging its public company platform to access and scale AI-driven opportunities, a move that could unlock substantial upside if management fees, carried interest, or equity appreciation from future acquisitions in AI data centers, power generation, or compute infrastructure—sectors experiencing explosive demand due to the AI boom. Management's explicit focus on evaluating AI infrastructure, software, data infrastructure, compute, and power generation assets reflects a structural shift toward capital-intensive, high-barrier-to-entry opportunities that align with long-term secular trends, positioning VTAK to benefit from multiple expansion as investors re-rate the company from a legacy medical device player to an AI infrastructure holding company with tangible operating assets and deal flow. The fact that VTAK led this investment as the largest shareholder, coupled with CEO David Jenkins' public endorsement of Volato's unique combination of technology assets and public market access, underscores confidence in the strategy's viability and suggests that further capital allocation toward similar AI opportunities is likely, potentially creating a virtuous cycle of deal sourcing, execution, and value creation that the market has not yet priced in.

▼ Bear case

VTAK's foray into AI infrastructure through its investment in Volato Group carries substantial execution and strategic risks that the market is overlooking, primarily because the company lacks demonstrable experience in scaling capital-intensive AI infrastructure projects such as data centers or power generation facilities, which require specialized engineering, regulatory navigation, and significant upfront capital—competencies not evident in VTAK's historical core business in catheter-based medical devices. The investment is structured as restricted common stock in Volato, a company with no revenue-generating AI infrastructure operations to date, relying instead on nascent initiatives like Volato AI and unsolicited non-binding letters of intent that carry no guarantee of conversion into definitive agreements, meaning VTAK's capital is effectively tied to speculative future transactions with uncertain timelines and outcomes, exposing it to the risk of sunk costs without tangible returns. Furthermore, Volato's own acknowledgment that it may not regain or maintain compliance with NYSE American continued listing standards introduces material counterparty risk; if Volato faces delisting or financial distress, VTAK's investment could suffer significant impairment, especially given the absence of hard assets or cash flow backing the valuation of this strategic stake. The broader AI infrastructure sector is also facing mounting headwinds, including power grid constraints, permitting delays, and rising interest rates that increase the cost of financing large-scale projects, factors that could delay or derail the very opportunities VTAK is betting on, while its lack of transparency around investment terms, ownership percentage post-investment, or expected return metrics makes it difficult for investors to assess the true risk-adjusted return of this pivot. Without clear financial commitments, milestones, or a defined pathway to monetize its AI infrastructure thesis, VTAK risks diverting management focus and capital from its core medical device business—where it has established competencies—toward a speculative strategy with no near-term revenue contribution, potentially eroding shareholder value if the AI transition fails to materialize as anticipated.

VTAK's foray into AI infrastructure through its investment in Volato Group carries substantial execution and strategic risks that the market is overlooking, primarily because the company lacks demonstrable experience in scaling capital-intensive AI infrastructure projects such as data centers or power generation facilities, which require specialized engineering, regulatory navigation, and significant upfront capital—competencies not evident in VTAK's historical core business in catheter-based medical devices. The investment is structured as restricted common stock in Volato, a company with no revenue-generating AI infrastructure operations to date, relying instead on nascent initiatives like Volato AI and unsolicited non-binding letters of intent that carry no guarantee of conversion into definitive agreements, meaning VTAK's capital is effectively tied to speculative future transactions with uncertain timelines and outcomes, exposing it to the risk of sunk costs without tangible returns. Furthermore, Volato's own acknowledgment that it may not regain or maintain compliance with NYSE American continued listing standards introduces material counterparty risk; if Volato faces delisting or financial distress, VTAK's investment could suffer significant impairment, especially given the absence of hard assets or cash flow backing the valuation of this strategic stake. The broader AI infrastructure sector is also facing mounting headwinds, including power grid constraints, permitting delays, and rising interest rates that increase the cost of financing large-scale projects, factors that could delay or derail the very opportunities VTAK is betting on, while its lack of transparency around investment terms, ownership percentage post-investment, or expected return metrics makes it difficult for investors to assess the true risk-adjusted return of this pivot. Without clear financial commitments, milestones, or a defined pathway to monetize its AI infrastructure thesis, VTAK risks diverting management focus and capital from its core medical device business—where it has established competencies—toward a speculative strategy with no near-term revenue contribution, potentially eroding shareholder value if the AI transition fails to materialize as anticipated.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password